FDA finalizes potency rules for cell and gene therapies, replacing its 2011 guidance

What the agency did

On November 2, 2026, the U.S. Food and Drug Administration published final guidance for industry titled Potency Assurance for Cellular and Gene Therapy Products. It finalizes a draft issued in December 2023 and supersedes the agency's January 2011 guidance on potency tests for these products. Potency means a product's ability to produce its intended biological effect.

What it says

Developers are expected to have a comprehensive potency assurance strategy rather than relying on a single test. At the licensing stage, each lot should be tested for potency with an assay performed after all manufacturing steps that could affect potency, and potency should be assured through the product's shelf life. Manufacturing changes must be assessed for their effect on potency, safety and effectiveness.

During clinical development, sponsors should describe their potency strategy in their investigational application, with more detail expected as trials grow, and the FDA may place a study on hold if potency information is lacking. The guidance calls for a risk-based approach across the product's lifecycle and covers raw material variability, in-process testing, short shelf-life products, viral vector gene therapies and individualized therapies.

What it does not do

This guidance does not approve any product or change the status of any therapy. FDA guidance documents describe the agency's current thinking and are not legally binding requirements. It does not address the many cell-based products marketed outside the FDA approval pathway.

The Youthful take

Cell and gene therapies are among the most hopeful directions in regenerative and longevity medicine, and their credibility depends on proof that every batch works the same way. Clearer potency standards should help well-run trials produce more trustworthy results. For patients, the practical message is unchanged: ask whether a cell or gene therapy is FDA approved or offered within a registered clinical trial before considering it.